Ineta Vaiciulyte

Ineta Vaiciulyte is a skilled QC Analyst at Custom Pharma Services since August 2022, specializing in hands-on analyses of finished products and problem-solving related to quality deviations. Prior experience includes roles as an Offshore Chemist at Benchmark Animal Health, where responsibilities involved water sample analysis and HPLC maintenance, and as an Analyst at Almac Group, conducting chemical analyses of pharmaceutical products per regulatory standards. Earlier experience as a Student Placement Analyst at Lonza Wood Protection included testing biocides and method development. Ineta holds an MSci in Forensic and Analytical Science with Industrial Experience from The University of Huddersfield and a BTEC Level 3 Extended Diploma in Applied Sciences from Peterborough College.

Location

Grays, United Kingdom

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Custom Pharma Services

1 followers

Custom Pharma Services is located in Brighton, UK since 1979 and is a full-service contract development and manufacturing organisation (CDMO) providing services tailored to your needs, no matter how niche or complex. Custom covers the full spectrum of activities from development through commercial manufacturing for both clinical and commercial use. Specialising in Oral Solid Dosage forms with the ability to handle highly potent drugs and poorly bioavailable compounds Custom really is your one stop resource. With direct access to highly skilled experts offering a partnership approach Custom Pharma Services truly has a molecule first mentality, managing all projects with the end in mind. Custom Can! • Custom Pharma is a CDMO offering clinical and commercial manufacturing of tablets, capsules, powders (oral-solid-dose) for human use. • Services comprise pre-formulation and formulation development, analytical development, stability testing, clinical trial material manufacturing • Commercial Production • Pre-clinical formulation development and solubilisation • Material characterisation • Drug in capsule approach to accelerate early clinical studies • Specialists in low dosage (sub-mg) formulations • Contained manufacturing for highly potent APIs • Orphan drug development • Formulation development of poorly soluble drugs, including spray drying capabilities


Employees

51-200

Links